Topic: hematologic diseases (he)
Title: Fibrinolytic Inhibitors in the Management of Bleeding Disorders.
Author: Tengborn, L.
Source: Montreal, Quebec: World Federation of Hemophilia. 2007. 16 p.
Availability: Available from World Federation of Hemophilia. 1425 Rene Levesque Boulevard West, Suite 1010, Montreal, Quebec H3G 1T7, Email: Website: Price: Available free of charge on website.
Abstract: This monograph describes the use of fibrinolytic inhibitors in the management of bleeding disorders. The author focuses on the synthetic derivative of the amino acid lysine, called epsilon-aminocaproic acid (EACA), and the more potent tranexamic acid (TA, also known as AMCA). The naturally occurring aprotinin is only briefly discussed because it is not principally used in patients with bleeding disorders. Topics include the activation of the fibrinolytic system, inhibitors in the fibrinolytic system, the pharmaceutical fibrinolytic inhibitors EACA and TA, and clinical uses in gynecology, bleeding in the gastrointestinal tract, bleeding in the nose and mouth, dental surgery, and major surgery. The author concludes that research studies support the beneficial effects of antifibrinolytic agents, most often TA, in patients apparently without congenital or acquired bleeding diseases. TA can be administered intravenously, orally, or topically, and no severe side effects have been documented. A table of abbreviations and list of references conclude the document. 1 figure. 1 table. 110 references.

Format: Monograph/Book
Language: English.
Major Keywords: Hematologic Diseases and Disorders. Bleeding Disorders. Delivery of Health Care. Guidelines. Coagulation. Hemorrhage. Patient Care Management. Drug Therapy.
Minor Keywords: First Aid. Risk Factors. Drug Effects. Oral Health. Gynecology. Fibrinolysis.
Publication Number: HEBK10187
Return to Search Results